Kyverna Therapeutics (KYTX) amended its loan agreement with Oxford Finance on July 8, 2026, effective June 30, 2026. The amendment extends the draw deadline for the remaining $15 million of Term A loans from June 30, 2026 to December 31, 2026, in exchange for a $187,500 fee. If Kyverna draws the full $15 million, the amendment also revises the terms for additional borrowings—a $5–20 million Term B loan and two $20 million Term C loans—each tied to achieving clinical or revenue milestones, and introduces minimum revenue covenants starting in the quarter ending June 30, 2027, September 30, 2027, or December 31, 2027, depending on other capital sources.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding KYVERNA THERAPEUTICS INC (KYTX)?

Major stakeholders currently include GordonMD Global Investments LP ($36.6M), Gilead Sciences, INC. ($35.6M), Bain Capital Life Sciences Investors, LLC ($26.8M). Based on the latest 13F filings, there are a total of 111 tracked investment funds and institutions maintaining positions in KYTX.

What is the overall institutional sentiment toward KYTX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $21.9M, driven by 56 managers accumulating shares while 49 reduced their exposure.

Which institutions have been selling or reducing their KYTX positions?

In the latest period, 35 funds trimmed their holdings, and 14 managers completely exited their positions. The aggregate reported sell value was $131.1M.

Are there any notable investors adding KYTX to their portfolios?

Yes, buying activity remains notable. 24 institutions opened new positions in {ticker}, and 32 existing holders added to their shares. The total reported buy value for the quarter amounted to $105.8M.